In addition, significant downregulation of the pro-angiogenic Vascular Endothelial Growth Factor A (VEGFA) post-C/T in Late Recurrence patients suggests that, in these patients, C/T could counteract the pro-tumor effects often mediated by VEGFA. The gene discussed is VEGFA; the disease is neoplasm.